NCT04962893 - Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine | Biotech Hunter

Enrollment

349

Participants

Timeline

Start Date

June 26, 2021

Primary Completion Date

January 16, 2022

Study Completion Date

January 16, 2022

Conditions

Covid19

Interventions

BIOLOGICAL

SARS-CoV-2 VLP Vaccine-Wuhan

Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus

BIOLOGICAL

SARS-CoV-2 VLP Vaccine-Alpha (British) variant

Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus

BIOLOGICAL

SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant

Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the Wuhan or Alpha variants

Trial Locations (3)

Health Sciences University İstanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul

Kocaeli University Research and Application Hospital Infectious Disease and Clinical Microbiology Department, Kocaeli

Dr. Abdurahman Yurtaslan Ankara Oncology Training and Research Hospital Phase I Clinical Study Center, Ankara